Trials / Conditions / Human Immunodeficiency Virus Infection

Human Immunodeficiency Virus Infection

20 registered clinical trials studyying Human Immunodeficiency Virus Infection.

Status	Trial	Sponsor	Phase
Unknown	HPV Infection, Sexually Transmitted Infections and Anal Dysplasia in the Transgender Population NCT05981807	ANRS, Emerging Infectious Diseases	—
Unknown	Awareness of Osteoporosis in HIV Patients NCT05769413	Uskudar State Hospital	—
Unknown	A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers NCT05141422	Jiangsu HengRui Medicine Co., Ltd.	Phase 1
Completed	Viral and Antiretroviral Dynamics in HIV-1 Mother-to-Child Transmission Fluids NCT03284645	Obafemi Awolowo University	—
Completed	Gene Expression Outcomes in Interventions for Substance Using HIV+ Minority Men NCT03143205	University of California, San Francisco	N/A
Completed	DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infect NCT02817451	Sanofi Pasteur, a Sanofi Company	Phase 3
Completed	A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepa NCT02738138	AbbVie	Phase 3
Completed	The Effect of an Enhanced Rice Bran Nutritional Supplement in HIV NCT02214173	University of Miami	N/A
Completed	A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-33 NCT01939197	AbbVie	Phase 2 / Phase 3
Completed	Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART NCT01869634	University of California, Davis	Phase 4
Withdrawn	A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects NCT01738555	RFS Pharma, LLC	Phase 2
Terminated	Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults NCT01791465	Vanderbilt University	Phase 4
Terminated	A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects. NCT01737359	RFS Pharma, LLC	Phase 2
Completed	Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program NCT01662336	AbbVie (prior sponsor, Abbott)	—
Completed	Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody NCT01447680	G & W Laboratories Inc.	—
Completed	Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets) NCT01383005	AbbVie (prior sponsor, Abbott)	—
Completed	Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection NCT01328158	AbbVie (prior sponsor, Abbott)	—
Completed	Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nuc NCT00711009	Abbott	Phase 3
Completed	Men Together Making a Difference: Reducing HIV/STD Risk Behavior Among South African Men NCT01490359	University of Pennsylvania	N/A
Completed	Long-term Effectiveness and Safety in Hepatitis-co-infected Patients NCT01153269	Abbott	—